Your Web Site
News source: Business Wire Invitrogen Corporation today announced results for its second quarter ended June 30, 2008. Revenues for the second quarter were $368 million, an increase of 14.3 percent over the $322 million reported for the second quarter of 2007. "We continue to see consistent, solid growth in our business, leading to yet another quarter of strong financial results," said Greg Lucier, Chairman and Chief Executive Officer of Invitrogen. "Once the transaction with Applied Biosystems is complete, we look forward to combining our strong portfolios, world-class systems and talented people to create a truly remarkable life sciences company." Second quarter diluted earnings per share were $0.55, which includes $0.05 per share of stock option expensing and $0.13 per share of amortization, business integration and other... [read full story]
